Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCAR015 in Adult B-cell ALL
NCT02973191Phase 2Withdrawn
- Sponsor
- Celgene Corporation
- Start
- Dec 2016
- Primary completion
- Jun 2019
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 7
01
Overview
A Phase 2 trial of Vadacabtagene leraleucel in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Celgene Corporation. Planned start Dec 2016; status: withdrawn.
02
Drugs
Vadacabtagene leraleucel
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT02973191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02973191.